Atrium Therapeutics, Inc. (RNA)
7.84
-0.30
(-3.69%)
USD |
NASDAQ |
Oct 02, 16:00
7.98
+0.14
(+1.79%)
After-Hours: 20:00
Atrium Therapeutics Debt to Equity Ratio : 0.0078 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0078 |
| March 31, 2026 | 0.0114 |
| December 31, 2025 | -0.0586 |
| Date | Value |
|---|---|
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | -0.1113 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Tenax Therapeutics, Inc. | 0.00 |
| Exicure, Inc. | 0.00 |
| Century Therapeutics, Inc. | 0.1664 |
| Absci Corp. | 0.0156 |
| Celularity, Inc. | -1.931 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 280.51M |
| Total Liabilities (Quarterly) | 65.94M |
| Shareholders Equity (Quarterly) | 214.58M |
| Current Ratio | 8.730 |
| Net Debt Paydown Yield | 0.44% |